Technology Prognosis

tracking technologies before you have to make a decision

Cablivi (Caplacizumab-yhdp)

February 7, 2019

Caplacizumab is a subcutaneously injected biologic agent intended for use as an adjunct to standard care for acquired thrombotic thrombocytopenic purpura. It is a bivalent single-domain anti-von Willebrand factor (VWF) nanobody that inhibits the binding of VWF to platelets to prevent the early stages of blood clot formation. Nanobodies are much smaller than conventional monoclonal antibodies, allowing for more rapid distribution, onset of action, and clearance.